Press Coverage
Corriere della Serra interviews Graziano Seghezzi after Sofinnova Partners signs deal with Apollo
Related Deal lead
Graziano SeghezziThe leading Italian daily Corriere della Serra described Sofinnova Partners' deal with Apollo as "one of the most important moves in recent years" for European venture capital.
The Sofinnova Managing Partner Graziano Seghezzi explained the logic of the deal to reporter Fabio Sottocornola: "Our idea is to remain completely independent in all decisions and investments," he said, adding that while Apollo would have a representative on the board, the American company would not have a say in investment or operational decisions.
Turning to the topic of his native Italy, Seghezzi explained that the biotech start-up scene is robust there, especially spin-outs coming from the academic sphere. The real challenge, he said, was in the scale-up stage. Italian biotechs, he said, would eventually need investments of between €20 million and €100 million. "Apollo can count on more than 1,500 investors on its books: this opens the door to worldwide fundraising," Seghezzi added.
In closing, the article highlighted the fact that the investment coincided with the first-ever Milan edition of Bioequity Week, a closed-door event that brings together venture capitalists, scientists and investors from all over the world.
Related Articles
Cédric Moreau discusses Apollo deal on "Journal des Biotechs"
Henrijette Richter discusses Apollo deal with Børsen: "You have to play in that arena"
Graziano Seghezzi tells Unquote that after Apollo deal, "We will continue to build on our strategy"
Papiernik tells Bloomberg that biotech is essential to pharma industry
Antoine Papiernik tells Le Figaro that Apollo deal will help Sofinnova finance the next generation of game-changing health care start-ups